Cargando…

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

The identification of recurrent driver mutations in genes encoding tyrosine kinases has resulted in the development of molecularly-targeted treatment strategies designed to improve outcomes for patients diagnosed with acute myeloid leukemia (AML). The receptor tyrosine kinase FLT3 is the most common...

Descripción completa

Detalles Bibliográficos
Autores principales:	Staudt, Dilana, Murray, Heather C., McLachlan, Tabitha, Alvaro, Frank, Enjeti, Anoop K., Verrills, Nicole M., Dun, Matthew D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214138/ https://www.ncbi.nlm.nih.gov/pubmed/30332834 http://dx.doi.org/10.3390/ijms19103198

Ejemplares similares

Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
por: Smith, Amanda M., et al.
Publicado: (2016)

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
por: Murray, Heather C., et al.
Publicado: (2020)

B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers
por: McLachlan, Tabitha, et al.
Publicado: (2022)

A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia
por: Enjeti, Anoop K., et al.
Publicado: (2016)

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia
por: Murray, Heather C., et al.
Publicado: (2023)

Disrupting autophagy in FLT3-mutant acute myeloid leukemia
por: Grant, Steven
Publicado: (2022)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection
por: Staudt, Dilana E., et al.
Publicado: (2022)

Correction to: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection
por: Staudt, Dilana E., et al.
Publicado: (2023)

Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia
por: Humphries, Sam, et al.
Publicado: (2023)

BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia
por: Stone, Richard M.
Publicado: (2020)

Targeting Apoptotic Pathways in Acute Myeloid Leukaemia
por: Sillar, Jonathan R., et al.
Publicado: (2019)

The Path of Least Resistance
por: Jalli, Sandeep S., et al.
Publicado: (2021)

Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia
por: Heydt, Q, et al.
Publicado: (2018)

scTEM-seq: Single-cell analysis of transposable element methylation to link global epigenetic heterogeneity with transcriptional programs
por: Hunt, Kooper V., et al.
Publicado: (2022)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

Detection of FLT3 Oncogene Mutations in Acute Myeloid Leukemia Using Conformation Sensitive Gel Electrophoresis
por: Gari, Mamdooh, et al.
Publicado: (2008)

19S Proteasome Subunits as Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML)
por: Lara, Joshua J., et al.
Publicado: (2022)

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2019)

Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
por: Garitano-Trojaola, Andoni, et al.
Publicado: (2021)

Evaluation of hypereosinophilia in a case of FLT3-mutant acute myeloid leukemia treated with gilteritinib
por: Martinez-Gutierrez, Leslie N., et al.
Publicado: (2023)

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia
por: Park, Jung Eun, et al.
Publicado: (2013)

Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD–negative acute myeloid leukemia
por: Qu, Shuang, et al.
Publicado: (2014)

Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD
por: Kazi, Julhash U., et al.
Publicado: (2017)

LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia
por: Yu, Zhou, et al.
Publicado: (2021)

FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018)

Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011)

Targeting FLT3 Mutations in Acute Myeloid Leukemia
por: El Fakih, Riad, et al.
Publicado: (2018)

Potential targeting of FLT3 acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2020)

Endocrine therapy: defining the path of least resistance
por: Stone, Andrew, et al.
Publicado: (2014)

Precision antimicrobial therapeutics: the path of least resistance?
por: Spaulding, Caitlin N., et al.
Publicado: (2018)

A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice
por: Mupo, A, et al.
Publicado: (2013)

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia
por: Braun, Theodore P., et al.
Publicado: (2019)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
por: Knight, Tristan E., et al.
Publicado: (2022)

Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios
por: Qiu, Kun-yin, et al.
Publicado: (2022)

Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
por: Wachholz, Vanessa, et al.
Publicado: (2021)

The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2013)

Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia
por: Sexauer, Amy N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9tfm3jfr0apg8j4avhhfdhm3ek